(Q44610471)

4 December 2017

title

Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle (English)

1 reference

4 December 2017

4

1 reference

4 December 2017

Pakrasi S

1

1 reference

4 December 2017

Mukaetova-Ladinska EB

series ordinal

2

1 reference

4 December 2017

McKeith IG

series ordinal

3

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

International Journal of Geriatric Psychiatry

4 December 2017

published in

1 reference

4 December 2017

volume

18

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

879-886

1 reference

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

4 December 2017

cites work

1 reference

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

An investigation of premedication with morphine given by the buccal or intramuscular route

21 January 2018

1 reference

Placebo response in depression: bane of research, boon to therapy.

21 January 2018

1 reference

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil

1 reference

7 January 2021

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

1 reference

7 January 2021

Dementia with Lewy bodies: diagnosis and management

1 reference

7 January 2021

Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?

1 reference

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

7 January 2021

Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice

1 reference

7 January 2021

Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies

1 reference

7 January 2021

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

1 reference

7 January 2021

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

7 January 2021

1 reference

7 January 2021

Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice.

1 reference

7 January 2021

Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?

1 reference

7 January 2021

Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial

1 reference

7 January 2021

Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk

1 reference

7 January 2021

Nicotinic receptor subtypes and cognitive function

1 reference

7 January 2021

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

1 reference

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

7 January 2021

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

1 reference

7 January 2021

Drugs for Alzheimer's disease

1 reference

7 January 2021

Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales

1 reference

7 January 2021

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

1 reference

7 January 2021

Nicotinic receptors in aging and dementia

1 reference

7 January 2021

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

1 reference

7 January 2021

Goal setting and attainment in Alzheimer's disease patients treated with donepezil

1 reference

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

7 January 2021

Moving out of the laboratory: does nicotine improve everyday attention?

1 reference

7 January 2021

Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.

1 reference

7 January 2021

How to define treatment success using cholinesterase inhibitors.

1 reference

7 January 2021

Practice effects on cognitive tasks: a major problem?

1 reference

7 January 2021

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.928

1 reference

4 December 2017

1 reference